Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
Key Highlights
- ➤Metagenomi CEO Jian Irish to present at Jefferies Global Healthcare Conference November 18
- ➤MGX-001 hemophilia A program demonstrated preclinical targeted genome editing and durable gene expression
- ➤Metagenomi plans to expand its pipeline through site-specific deletion, insertion and correction capabilities
Expert Statements
Jian Irish, President and Chief Executive Officer of Metagenomi Therapeutics
“No qualifying direct quote or clearly attributed statement provided in the article.”
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in London, UK, on Wednesday, November 18, 2026, at 12:00 p.m. ET.
A live webcast of the event will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.
Get started
Create a free account to read the full story.